# Arvaya Healthcare share price today (Arvaya Healthcare Ltd, NSE: ARVAYA) > Arvaya Healthcare share price today: ₹101.65 at the BSE close on 17 November 2026. Arvaya Healthcare (NSE: ARVAYA) is worth ₹488 crore. > Arvaya Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ARVAYA · Trading · data as of 17 November 2026. Page: https://www.sectoralpha.in/stocks/arvaya-healthcare-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹101.65 - Revenue (Jun 2026): ₹0.1 Cr - Profit (Jun 2026), incl. one-off: −₹0.9 Cr (one-off item, see below) - Operating margin: −810.0% Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Arvaya Healthcare share price today? Arvaya Healthcare Ltd's share price was ₹101.65 at the close on 17 November 2026. It has been rising for 61 weeks. That is 28.3% above its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running. Since its first close in our records, on 24 June 2026, it has traded between ₹67 and ₹142, and at that close it sat 46% of the way up from that low. Over the last 5 months the share price moved +51% while the NIFTY 500 moved +3%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 27 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Arvaya Healthcare this quarter? 3 points in one quarter. 1. Lowest operating margin in 9 quarters Operating margin was -810% in the June 2026 quarter. 2. Promoters cut their stake by 2.3 points in one quarter From 30.6% to 28.3% in the October 2026 quarter. ## What are Arvaya Healthcare's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Arvaya Healthcare reported revenue of ₹0.10 crore, and a loss of ₹0.89 crore. ### Arvaya Healthcare results: April to June 2026 against a year earlier | Measure | April to June 2026 | April to June 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹0.10 crore | ₹0.00 crore | n/a | | Profit | loss of ₹0.89 crore | loss of ₹0.25 crore | n/a | | Earnings per share | ₹−0.19 | ₹−0.33 | n/a | | Operating margin | −810.0% | n/a | n/a | The next results, for July to September 2026, were due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.) ## What is the Arvaya Healthcare share price history? Arvaya Healthcare closed at ₹101.65 on 17 November 2026. Its highest weekly close since June 2026 was ₹139.41 on 24 July 2026. ### Arvaya Healthcare share price: then and now | When | Close | Change to 17 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹111.20 | −8.6% | | 1 month ago · 16 Oct 2026 | ₹98.85 | +2.8% | | Earliest and lowest weekly close in our records · 24 Jun 2026 | ₹67.11 | +51.5% | | Highest weekly close since June 2026 · 24 Jul 2026 | ₹139.41 | −27.1% | Weekly closing prices. Each change is the move from that price to the 17 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (20 weekly closes from 24 June 2026 to 17 November 2026.) ## What is the latest news on Arvaya Healthcare? 17 Nov 2026: Arvaya Healthcare closed at ₹101.65, down 8.6% on the week and up 2.8% on the month. ## What dividend does Arvaya Healthcare pay? Arvaya Healthcare has paid no dividend on the NSE since its first NSE close in our records (24 June 2026), the start of the period we checked. No. Arvaya Healthcare Ltd paid out 0% of its profit as dividends in each of its last 11 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 18 November 2026.) ## What to watch in Arvaya Healthcare's next results? When Arvaya Healthcare reports July to September 2026, this is the check that shows whether the story is still on course: Whether the operating margin stays near −810.0%. - Whether the operating margin stays near −810.0%. The latest full year's operating margin was the highest on file. Every ratio built on profit looks better at a peak. ## Which stock lists is Arvaya Healthcare on? Arvaya Healthcare is not on any of our India lists this week. ## Is Arvaya Healthcare profitable? Arvaya Healthcare Ltd posted a net loss of ₹0.9 Cr in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of ₹1.2 Cr. The Jun 2026 quarter's loss is 890.0% of that quarter's revenue. The same quarter a year earlier lost ₹0.3 Cr. 11 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was −₹1.2 Cr (−957.1% on the year before). Read this profit with care: at −₹0.9 Cr it is bigger than the quarter's whole revenue of ₹0.1 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −810.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Arvaya Healthcare make, and is it growing? Arvaya Healthcare Ltd reported ₹0.1 Cr of revenue in the Jun 2026 quarter. The last full year, FY26, came in at ₹0.0 Cr. The last four reported quarters add to ₹0.1 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. FY26 revenue was ₹0.0 Cr, −100.0% on the year before. Is growth speeding up? Revenue over the last 12 months grew −47.4%, against −42.3% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Arvaya Healthcare keep? Arvaya Healthcare Ltd's operating margin was −810.0% in the Jun 2026 quarter. Its latest full-year margin is the highest it has ever reported. Across 12 years it has been between −185.7% and 8.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −538.6 percentage points on the year while gross margin changed +0.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Arvaya Healthcare's profit turning into cash? Arvaya Healthcare Ltd's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used ₹7.9 Cr of cash, against −₹1.2 Cr of profit. After ₹0.0 Cr of estimated spending on assets (worked out from the change in fixed assets plus depreciation; no filed figure), free cash was −₹8.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. ## Where does Arvaya Healthcare's cash go? Arvaya Healthcare Ltd's customer, stock and supplier day counts are not a useful reading on sales this small (₹0.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹0.0 Cr on assets over the last 3 years. Spending on assets: ₹0.0 Cr over the last 3 years. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: almost nothing is being spent on new assets, so the cash goes on running the business. ## What is Arvaya Healthcare's P/E ratio, and how does it compare with its own history? Arvaya Healthcare Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Arvaya Healthcare business getting better or worse? Arvaya Healthcare Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Arvaya Healthcare earn on its capital? Arvaya Healthcare Ltd earned a ROCE of −4% in FY26. That is up from a low of −12% in FY23. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 50.0% net margin and 0.08× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 50.0% net margin × 0.08× asset turnover × 1.02× leverage (assets divided by equity) ≈ 4.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. ## Does Arvaya Healthcare have too much debt? Arvaya Healthcare Ltd had ₹2.5 Cr of borrowings against ₹58.0 Cr of equity in FY26, so its debt is 0.04× its equity. Over 5 years borrowings went from ₹0.0 Cr to ₹2.5 Cr. Over the last 3 of those years it spent ₹0.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Arvaya Healthcare shareholding pattern? Promoters raised their stake in Arvaya Healthcare Ltd by 20.6 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 28.3% of the company. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why the owners changed: promoters drove it (+20.6 points). They raised their stake step by step. ## How far is Arvaya Healthcare from balance-sheet trouble? For Arvaya Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Arvaya Healthcare rank in its industry? 45.3 out of 100, rank 59 of 65 in Trading, with 46% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Arvaya Healthcare Ltd scores 45.3 out of 100 against the 65 companies it is compared with in Trading, ranking 59. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 19.5 + 3.9 + 10 + 11.9 = 45.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Arvaya Healthcare compared with? Arvaya Healthcare ranks 59 of 65 Trading companies on the 4-Factor Sector Score, with 45.3 out of 100. 1. [Shankara Buildpro Ltd](https://www.sectoralpha.in/stocks/shankara-buildpro-ltd) BUILDPRO · quiet · Most evidence points up · 63% evidence 67.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.4/43.75 · Revenue 30.2% · Profit 38% · Operating margin change 0.3 points · 100% evidence Capital efficiency 23.2/31.25 · ROCE 39% (year to Mar 2026) · Operating margin 3.4% · 100% evidence Valuation 13.3/25 · P/E 15.5× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.4 + 23.2 + 13.3 = 67.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 2. [Mangalam Global Enterprise Ltd](https://www.sectoralpha.in/stocks/mangalam-global-enterprise-ltd) MGEL · breaking out · Most evidence points up · 83% evidence 65.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidence Capital efficiency 14.8/25 · ROCE 17% (year to Mar 2026) · Operating margin 2.3% · 100% evidence Valuation 10.8/20 · P/E 14.4× · PEG n/a · 15% evidence Relative strength 17.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.6% · Strength vs NIFTY 500 (same reading) 19.3% · 1 year 13.8% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.4 + 14.8 + 10.8 + 17.9 = 65.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Nupur Recyclers Ltd](https://www.sectoralpha.in/stocks/nupur-recyclers-ltd) NRL · leader · Most evidence points up · 82% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 79.3% · Profit 71.5% · Operating margin change 2.9 points · 95% evidence Capital efficiency 15.0/25 · ROCE 15.1% (year to Mar 2026) · Operating margin 9.9% · 76% evidence Valuation 7.7/20 · P/E 63.7× · PEG n/a · 50% evidence Relative strength 19.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 76.1% · Strength vs NIFTY 500 (same reading) 90.2% · 1 year 216.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 15 + 7.7 + 19.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Rashi Peripherals Ltd](https://www.sectoralpha.in/stocks/rashi-peripherals-ltd) RPTECH · losing its lead · Evidence leans up · 82% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.0/35 · Revenue 51.1% · Profit 93.2% · Operating margin change 1.1 points · 95% evidence Capital efficiency 15.1/25 · ROCE 17% (year to Mar 2026) · Operating margin 3.6% · 76% evidence Valuation 10.8/20 · P/E 10.7× · PEG n/a · 50% evidence Relative strength 11.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 6.2% · Strength vs NIFTY 500 (same reading) 15.3% · 1 year 90.7% · 100% evidence · 9 of 12 weeks ahead Exact sum: 27 + 15.1 + 10.8 + 11.7 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Bhatia Communications & Retail (India) Ltd](https://www.sectoralpha.in/stocks/bhatia-communications-retail-indialtd) turning · Evidence leans up · 72% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 55.2% · Profit 72.1% · Operating margin change 1.5 points · 95% evidence Capital efficiency 18.6/25 · ROCE 21.3% (year to Mar 2026) · Operating margin 5.7% · 95% evidence Valuation 9.3/20 · P/E 25× · PEG n/a · 50% evidence Relative strength 11.8/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 39.8% · 1 year n/a · 25% evidence · 1 of 1 week ahead Exact sum: 23.9 + 18.6 + 9.3 + 11.8 = 63.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 6. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) turning · Too little evidence to rank firmly · 57% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 100% · Profit 100% · Operating margin change -0.2 points · 71% evidence Capital efficiency 16.2/25 · ROCE 23.5% (year to Mar 2026) · Operating margin 1.6% · 95% evidence Valuation 11.4/20 · P/E 1.1× · PEG n/a · 15% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 100.1% · 1 year n/a · 25% evidence · 1 of 1 week ahead Exact sum: 23.6 + 16.2 + 11.4 + 12.3 = 63.5 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Arisinfra Solutions Ltd](https://www.sectoralpha.in/stocks/arisinfra-solutions-ltd) ARIS · breaking out · Evidence leans up · 60% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.7/35 · Revenue 41.7% · Profit 100% · Operating margin change 3 points · 95% evidence Capital efficiency 13.8/25 · ROCE 15.6% (year to Mar 2026) · Operating margin 11.7% · 76% evidence Valuation 10.5/20 · P/E 16.4× · PEG n/a · 15% evidence Relative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 13.6% · 1 year -3.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 27.7 + 13.8 + 10.5 + 11.2 = 63.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [SG Mart Ltd](https://www.sectoralpha.in/stocks/sg-mart-ltd) SGMART · leader · Evidence leans up · 83% evidence 61.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidence Capital efficiency 11.6/25 · ROCE 10.2% (year to Mar 2026) · Operating margin 4.6% · 100% evidence Valuation 9.3/20 · P/E 85.2× · PEG n/a · 15% evidence Relative strength 18.4/20 · Strength vs its industry (price vs its 52-week average, weekly) 43.2% · Strength vs NIFTY 500 (same reading) 56.8% · 1 year 194.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22 + 11.6 + 9.3 + 18.4 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Dhunseri Ventures Ltd](https://www.sectoralpha.in/stocks/dhunseri-ventures-ltd) DVL · breaking out · Evidence leans up · 74% evidence 61.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue 21.4% · Profit 100% · Operating margin change 82 points · 71% evidence Capital efficiency 11.1/25 · ROCE 6.7% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 12.8/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 15.6/20 · Strength vs its industry (price vs its 52-week average, weekly) 1.5% · Strength vs NIFTY 500 (same reading) 14.8% · 1 year 5.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.8 + 11.1 + 12.8 + 15.6 = 61.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DC Infotech & Communication Ltd](https://www.sectoralpha.in/stocks/dc-infotech-communication-ltd) DCI · quiet · Evidence leans up · 75% evidence 61.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 33.9% · Profit 37.6% · Operating margin change -0.3 points · 100% evidence Capital efficiency 16.6/25 · ROCE 23% (year to Mar 2026) · Operating margin 5.2% · 100% evidence Valuation 10.4/20 · P/E 23.5× · PEG n/a · 50% evidence Relative strength 11.1/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 12.1% · 1 year n/a · 25% evidence · 6 of 8 weeks ahead Exact sum: 22.9 + 16.6 + 10.4 + 11.1 = 61 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [Singer India Ltd](https://www.sectoralpha.in/stocks/singer-india-ltd) SINGERIND · breaking out · Evidence leans up · 68% evidence 59.9 out of 100 Growth Capital Valuation Relative 12. [Ivalue Infosolutions Ltd](https://www.sectoralpha.in/stocks/ivalue-infosolutions-ltd) IVALUE · quiet · Evidence leans up · 78% evidence 58.3 out of 100 Growth Capital Valuation Relative 13. Aayush Art and Bullion Ltd leader · Too little evidence to rank firmly · 59% evidence 58.0 out of 100 Growth Capital Valuation Relative 14. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) VIESL · losing its lead · Too little evidence to rank firmly · 60% evidence 57.6 out of 100 Growth Capital Valuation Relative 15. [Patel Retail Ltd](https://www.sectoralpha.in/stocks/patel-retail-ltd) PATELRMART · breaking out · Evidence leans up · 68% evidence 57.3 out of 100 Growth Capital Valuation Relative 16. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) TEMBO · quiet · Evidence leans up · 71% evidence 57.2 out of 100 Growth Capital Valuation Relative 17. [Euro Pratik Sales Ltd](https://www.sectoralpha.in/stocks/euro-pratik-sales-ltd) EUROPRATIK · basing · Evidence leans up · 68% evidence 55.2 out of 100 Growth Capital Valuation Relative 18. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) PROSTARM · quiet · Evidence leans up · 68% evidence 54.7 out of 100 Growth Capital Valuation Relative 19. [Mardia Samyoung Capillary Tubes Company Ltd](https://www.sectoralpha.in/stocks/mardia-samyoung-capillary-tubes-company-ltd) MSCTC · Evidence leans up · 60% evidence 52.5 out of 100 Growth Capital Valuation Relative 20. BMW Ventures Ltd BMW · breaking out · Evidence leans up · 60% evidence 51.7 out of 100 Growth Capital Valuation Relative 21. [MMTC Ltd](https://www.sectoralpha.in/stocks/mmtc-ltd) MMTC · quiet · Evidence leans up · 86% evidence 50.9 out of 100 Growth Capital Valuation Relative 22. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) TRANSCHEM · turning · Evidence leans up · 60% evidence 50.8 out of 100 Growth Capital Valuation Relative 23. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) SHIVAUM · breaking out · Evidence leans up · 67% evidence 50.6 out of 100 Growth Capital Valuation Relative 24. [Cropster Agro Ltd](https://www.sectoralpha.in/stocks/cropster-agro-ltd) CROPSTER · Evidence leans down · 60% evidence 49.6 out of 100 Growth Capital Valuation Relative 25. [Sudarshan Pharma Industries Ltd](https://www.sectoralpha.in/stocks/sudarshan-pharma-industries-ltd) quiet · Evidence leans down · 87% evidence 48.8 out of 100 Growth Capital Valuation Relative 26. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) HEXATRADEX · quiet · Evidence leans down · 74% evidence 44.9 out of 100 Growth Capital Valuation Relative 27. [Adani Enterprises Ltd](https://www.sectoralpha.in/stocks/adani-enterprises-ltd) ADANIENT · quiet · Evidence leans down · 93% evidence 44.5 out of 100 Growth Capital Valuation Relative 28. [A-1 Ltd](https://www.sectoralpha.in/stocks/a-1-ltd) A1L · Evidence leans down · 60% evidence 43.5 out of 100 Growth Capital Valuation Relative 29. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) BPAGRI · basing · Too little evidence to rank firmly · 57% evidence 43.1 out of 100 Growth Capital Valuation Relative 30. [Lloyds Enterprises Ltd](https://www.sectoralpha.in/stocks/lloyds-enterprises-ltd) LLOYDSENT · quiet · Evidence leans down · 75% evidence 40.7 out of 100 Growth Capital Valuation Relative 31. [Shanti Overseas (India) Ltd](https://www.sectoralpha.in/stocks/shanti-overseas-indialtd) SHANTI · Evidence leans down · 61% evidence 39.0 out of 100 Growth Capital Valuation Relative 32. [Riddhi Siddhi Gluco Biols Ltd](https://www.sectoralpha.in/stocks/riddhi-siddhi-gluco-biols-ltd) quiet · Evidence leans down · 87% evidence 37.5 out of 100 Growth Capital Valuation Relative 33. [Fabtech Technologies Ltd](https://www.sectoralpha.in/stocks/fabtech-technologies-ltd) FABTECH · basing · Evidence leans down · 68% evidence 37.0 out of 100 Growth Capital Valuation Relative 34. [PTC India Ltd](https://www.sectoralpha.in/stocks/ptc-india-ltd) PTC · quiet · Evidence leans down · 82% evidence 35.8 out of 100 Growth Capital Valuation Relative 35. [Uniphos Enterprises Ltd](https://www.sectoralpha.in/stocks/uniphos-enterprises-ltd) UNIENTER · basing · Evidence leans down · 75% evidence 35.8 out of 100 Growth Capital Valuation Relative 36. [Hardwyn India Ltd](https://www.sectoralpha.in/stocks/hardwyn-india-ltd) HARDWYN · quiet · Evidence leans down · 90% evidence 35.7 out of 100 Growth Capital Valuation Relative 37. [Shah Foods Ltd](https://www.sectoralpha.in/stocks/shah-foods-ltd) quiet · Too little evidence to rank firmly · 53% evidence 34.5 out of 100 Growth Capital Valuation Relative 38. Manbro Industries Ltd Too little evidence to rank firmly · 52% evidence 33.3 out of 100 Growth Capital Valuation Relative 39. [BN Agrochem Ltd](https://www.sectoralpha.in/stocks/bn-agrochem-ltd) BNAGROCHEM · basing · Most evidence points down · 64% evidence 33.2 out of 100 Growth Capital Valuation Relative 40. [Kothari Industrial Corporation Ltd](https://www.sectoralpha.in/stocks/kothari-industrial-corporation-ltd) KOTIC · quiet · Too little evidence to rank firmly · 53% evidence 33.2 out of 100 Growth Capital Valuation Relative 41. [Neueon Corporation Ltd](https://www.sectoralpha.in/stocks/neueon-corporation-ltd) NEUEON · quiet · Too little evidence to rank firmly · 56% evidence 32.1 out of 100 Growth Capital Valuation Relative 42. [Oswal Agro Mills Ltd](https://www.sectoralpha.in/stocks/oswal-agro-mills-ltd) OSWALAGRO · basing · Most evidence points down · 60% evidence 30.6 out of 100 Growth Capital Valuation Relative 43. [Le Merite Exports Ltd](https://www.sectoralpha.in/stocks/le-merite-exports-ltd) LEMERITE · Too little evidence to rank firmly · 58% evidence 26.7 out of 100 Growth Capital Valuation Relative 44. [Yogi Ltd](https://www.sectoralpha.in/stocks/yogi-ltd) YOGI · turning · Most evidence points down · 70% evidence 24.9 out of 100 Growth Capital Valuation Relative 45. [Pervasive Commodities Ltd](https://www.sectoralpha.in/stocks/pervasive-commodities-ltd) breaking out · Too little evidence to rank firmly · 47% evidence 64.5 out of 100 Growth Capital Valuation Relative 46. [Magnus Steel & Infra Ltd](https://www.sectoralpha.in/stocks/magnus-steel-infra-ltd) Too little evidence to rank firmly · 40% evidence 61.2 out of 100 Growth Capital Valuation Relative 47. [Susan Electricals India Ltd](https://www.sectoralpha.in/stocks/susan-electricals-india-ltd) Too little evidence to rank firmly · 36% evidence 60.0 out of 100 Growth Capital Valuation Relative 48. [Q-Line Biotech Ltd](https://www.sectoralpha.in/stocks/q-line-biotech-ltd) QLINE · quiet · Too little evidence to rank firmly · 31% evidence 59.7 out of 100 Growth Capital Valuation Relative 49. [Bizotic Commercial Ltd](https://www.sectoralpha.in/stocks/bizotic-commercial-ltd) BIZOTIC · quiet · Too little evidence to rank firmly · 38% evidence 59.5 out of 100 Growth Capital Valuation Relative 50. [Pramara Promotions Ltd](https://www.sectoralpha.in/stocks/pramara-promotions-ltd) PRAMARA · Too little evidence to rank firmly · 42% evidence 58.6 out of 100 Growth Capital Valuation Relative 51. [HP Telecom India Ltd](https://www.sectoralpha.in/stocks/hp-telecom-india-ltd) HPTL · turning · Too little evidence to rank firmly · 43% evidence 58.2 out of 100 Growth Capital Valuation Relative 52. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) turning · Too little evidence to rank firmly · 41% evidence 55.4 out of 100 Growth Capital Valuation Relative 53. [Proventus Agrocom Ltd](https://www.sectoralpha.in/stocks/proventus-agrocom-ltd) PROV · breaking out · Too little evidence to rank firmly · 50% evidence 55.1 out of 100 Growth Capital Valuation Relative 54. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) quiet · Too little evidence to rank firmly · 45% evidence 53.6 out of 100 Growth Capital Valuation Relative 55. [Monika Alcobev Ltd](https://www.sectoralpha.in/stocks/monika-alcobev-ltd) MONIKA · Too little evidence to rank firmly · 22% evidence 52.4 out of 100 Growth Capital Valuation Relative 56. [State Trading Corporation of India Ltd](https://www.sectoralpha.in/stocks/state-trading-corporation-of-india-ltd) STCINDIA · basing · Too little evidence to rank firmly · 47% evidence 50.7 out of 100 Growth Capital Valuation Relative 57. AUDROC Ltd Too little evidence to rank firmly · 43% evidence 47.1 out of 100 Growth Capital Valuation Relative 58. [Onix Solar Energy Ltd](https://www.sectoralpha.in/stocks/onix-solar-energy-ltd) ONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence 46.3 out of 100 Growth Capital Valuation Relative 59. Arvaya Healthcare Ltd this page ARVAYA · turning · Too little evidence to rank firmly · 46% evidence 45.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.5/35 · Revenue -47.4% · Profit -80% · Operating margin change 46.1 points · 62% evidence Capital efficiency 3.9/25 · ROCE -3.8% (year to Mar 2026) · Operating margin -810% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 48.2% · 1 year n/a · 25% evidence · 2 of 7 weeks ahead Exact sum: 19.5 + 3.9 + 10 + 11.9 = 45.3 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 60. C K K Retail Mart Ltd CKKRETAIL · Too little evidence to rank firmly · 36% evidence 45.3 out of 100 Growth Capital Valuation Relative 61. [Prabhatam Infra Venture Ltd](https://www.sectoralpha.in/stocks/prabhatam-infra-venture-ltd) turning · Too little evidence to rank firmly · 27% evidence 45.1 out of 100 Growth Capital Valuation Relative 62. [Satani Bearings Ltd](https://www.sectoralpha.in/stocks/satani-bearings-ltd) breaking out · Too little evidence to rank firmly · 43% evidence 43.0 out of 100 Growth Capital Valuation Relative 63. [Keto Motors Ltd](https://www.sectoralpha.in/stocks/keto-motors-ltd) quiet · Too little evidence to rank firmly · 43% evidence 39.8 out of 100 Growth Capital Valuation Relative 64. [Aerpace Industries Ltd](https://www.sectoralpha.in/stocks/aerpace-industries-ltd) breaking out · Too little evidence to rank firmly · 36% evidence 38.4 out of 100 Growth Capital Valuation Relative 65. [RRP Semiconductor Ltd](https://www.sectoralpha.in/stocks/rrp-semiconductor-ltd) RRP · Too little evidence to rank firmly · 47% evidence 35.6 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Trading](https://www.sectoralpha.in/sectors/trading), all 65 compared on one page. ## Which companies are close to Arvaya Healthcare in size? Arvaya Healthcare is the 49th largest of 61 Trading companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Transchem, Mardia Samyoung Capillary Tubes Company and SK Minerals & Additives. Just below it: Riddhi Siddhi Gluco Biols, Oswal Agro Mills and Blue Pearl Agriventures. ### Trading companies close in size 1. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) ₹503 crore 2. [Mardia Samyoung Capillary Tubes Company Ltd](https://www.sectoralpha.in/stocks/mardia-samyoung-capillary-tubes-company-ltd) ₹503 crore 3. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) ₹497 crore 4. Arvaya Healthcare Ltd ₹488 crore 5. [Riddhi Siddhi Gluco Biols Ltd](https://www.sectoralpha.in/stocks/riddhi-siddhi-gluco-biols-ltd) ₹482 crore 6. [Oswal Agro Mills Ltd](https://www.sectoralpha.in/stocks/oswal-agro-mills-ltd) ₹468 crore 7. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) ₹465 crore [All 61 Trading companies, largest first](https://www.sectoralpha.in/sectors/trading#all-companies) ### Companies close in size in other industries 1. [Omax Autos Ltd](https://www.sectoralpha.in/stocks/omax-autos-ltd) ₹488 crore · Auto Ancillaries - Sheet Metal 2. [Shriram Asset Management Co Ltd](https://www.sectoralpha.in/stocks/shriram-asset-management-co-ltd) ₹488 crore 3. Arvaya Healthcare Ltd ₹488 crore 4. [Aptech Ltd](https://www.sectoralpha.in/stocks/aptech-ltd) ₹488 crore · Computer Education 5. [Credo Brands Marketing Ltd](https://www.sectoralpha.in/stocks/credo-brands-marketing-ltd) ₹488 crore · Textiles - Readymade Apparel ## What else do people ask about Arvaya Healthcare? ### What were Arvaya Healthcare's latest quarterly results? Arvaya Healthcare Ltd reported revenue of ₹0.1 Cr and a net loss of ₹0.9 Cr for the Jun 2026 quarter. Earnings per share were −₹0.19. The operating margin was −810.0% (as of 17 November 2026). ### What is Arvaya Healthcare's market cap? Arvaya Healthcare Ltd's market capitalisation is ₹488 Cr at a share price of ₹101.65. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 17 November 2026). ### How is Arvaya Healthcare performing? Arvaya Healthcare Ltd's share price has been rising for 61 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 4 weeks running. This describes what the data did, not a rating (as of 17 November 2026). ### Will Arvaya Healthcare's share price go up? This page does not forecast Arvaya Healthcare Ltd's share price. What it shows instead: the share price is ₹101.65, and it has been rising for 61 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 17 November 2026). ### Who owns Arvaya Healthcare? Promoters own 28.3% of Arvaya Healthcare Ltd, foreign institutions , domestic institutions, and the public 71.7% (latest quarter). The biggest change over the last two years: Promoters raised their stake by 20.6 percentage points over 8 quarters (as of 17 November 2026). ### Where is Arvaya Healthcare in its business cycle? Arvaya Healthcare Ltd's FY26 operating margin was 8.0%, against a 12-year range of −185.7% to 8.0%. The latest quarter was −810.0%, below the bottom of its own yearly range in the latest quarter, a low point in its cycle. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 17 November 2026). ### What could break the Arvaya Healthcare story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 17 November 2026). ### Is Arvaya Healthcare a stock worth studying right now? What the numbers show: Arvaya Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 17 November 2026). This is research, not advice. We’re not SEBI-registered.